Related Experiment Videos
Antiblastic drug combinations with ifosfamide: an update
F Fulfaro1, M R Valerio, G Badalamenti
1Department of Oncology, University of Palermo, Palermo, Italy. chemotherapy@inwind.it
Oncology
|October 31, 2003
Summary
Ifosfamide is a versatile chemotherapy drug for various cancers. Optimizing its dosage and scheduling with other agents is crucial for maximizing treatment effectiveness and patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Background:
- Ifosfamide is a widely used alkylating agent for treating diverse neoplasms.
- Its clinical toxicity is dose and schedule dependent.
- It can be combined with other antineoplastic agents and used in refractory cases.
Purpose of the Study:
- To review the role of ifosfamide in cancer treatment.
- To discuss its combination therapy and use in treatment-resistant cancers.
- To highlight the need for optimizing dosing and scheduling with novel chemotherapeutics.
Main Methods:
- Literature review of ifosfamide's clinical applications.
- Analysis of its pharmacologic profile and combination therapies.
- Discussion of pharmacokinetic and pharmacodynamic considerations.
Main Results:
- Ifosfamide demonstrates efficacy across various cancers including sarcomas, lymphomas, and germ cell tumors.
- It shows promise in patients with prior treatment failures.
- Combinations with agents like vinorelbine, gemcitabine, paclitaxel, and docetaxel are feasible.
Conclusions:
- Optimizing ifosfamide dosing and scheduling is essential for enhancing therapeutic efficacy.
- Clinical trials incorporating pharmacokinetic and pharmacodynamic studies are recommended.
- Further research is needed to refine its use with novel chemotherapeutic agents.